Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

Despite recent advances in the treatment of multiple myeloma, patients with this disease still inevitably relapse and become refractory to existing therapies. Mutations in K-RAS, N-RAS and B-RAF are common in multiple myeloma, affecting 50% of patients at diagnosis and >70% at relapse. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishnan, Vijay G., Miller, Kevin C., Macon, Elaine P., Kimlinger, Teresa K., Haug, Jessica, Kumar, Sanjay, Gonsalves, Wilson I., Rajkumar, S. Vincent, Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886422/
https://www.ncbi.nlm.nih.gov/pubmed/30846494
http://dx.doi.org/10.3324/haematol.2018.211110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886422/
https://www.ncbi.nlm.nih.gov/pubmed/30846494
http://dx.doi.org/10.3324/haematol.2018.211110

Ejemplares similares